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One Sentence Summary: Genetics, pathology and molecular studies demonstrate that 
miR-218 is modulated and might play a role in amyotrophic lateral sclerosis.  
Abstract: Motor-neuron specific microRNA-218 (miR-218) has recently received 
attention because of its roles in mouse development. However, miR-218 relevance to 
human motor neuron disease was not yet explored. Here, we demonstrate by 
neuropathology that miR-218 is abundant in healthy human motor neurons. However, in 
amyotrophic lateral sclerosis (ALS) motor neurons miR-218 is downregulated and its 
mRNA targets are reciprocally upregulated (de-repressed). We further identify the 
potassium channel Kv10.1 as a new miR-218 direct target that controls neuronal activity. 
In addition, we screened thousands of ALS genomes and identified six rare variants in the 
human miR-218-2 sequence. miR-218 gene variants fail to regulate neuron activity, 
suggesting the importance of this small endogenous RNA for neuronal robustness. The 
underlying mechanisms involve inhibition of miR-218 biogenesis and reduced processing 
by DICER. Therefore, miR-218 activity in motor neurons may be susceptible to failure in 
human ALS suggesting that miR-218 may be a potential therapeutic target in motor neuron 
disease.  
[Main Text: ] 
Introduction 
microRNA-218 (miR-218) is an endogenous small RNA that is enriched in motor neurons. 
Its relevance to motor neuron diseases was recently suggested by showing that miR-218 is 
essential for perinatal neuromuscular survival (1, 2), it is decreased in human amyotrophic 
lateral sclerosis (ALS) post-mortem spinal cord (3, 4), that cell-free miR-218 can serve as 
marker for motor neuron loss in a rodent model of ALS (4) and as a neuron-to-astrocyte 
signal (5). However, miR-218 was not yet studied in human motor neurons and relevance 
to human ALS is still missing.  
ALS is a fatal disease of the human motor neuron system, characterized by the selective 
degeneration of cortical and ventral spinal motor neurons.  
More than two dozen different genes have been associated with ALS in families or via 
genome-wide association studies. Mutations in these genes explain only a small fraction of 
the cases (6-9). Thus, ALS genetic variants in SOD1, NEK1, TARDBP or FUS are observed 
in <1-3% of cases and the fraction of disease explained by the hexanucleotide repeat at the 
first exon of C9orf72 is <10% (6, 10). ALS-associated genes are ubiquitously expressed 
and therefore provide limited insight as to why ALS shows motor neuron-selective 
vulnerability (8, 11). 
Differential susceptibilities could be explained by the dysregulated activity of cell-type 
specific genes, including miRNAs. Indeed, we and others have shown that miRNA 
dysregulation is involved in ALS (3, 12-18). 
In this study, we demonstrate (i) that miR-218 is specifically enriched in human spinal 
motor neurons and is downregulated in ALS, (ii) that miR-218 orchestrates neuronal 
activity in a new pathway upstream of Kv10.1 (Kcnh1) voltage-gated potassium channel 
and (iii) that rare genetic miR-218 variants, identified in patients with ALS, are detrimental 
to its biogenesis and function, providing a connection from human genetics to motor 
neuron-specific functions.  
Results  
miR-218 is highly and specifically expressed in mature human and murine motor neurons 
We sought to evaluate the relevance of miR-218 to human motor neuron and its relevance 
to ALS. First, miRNA in situ hybridization in human tissues depicted motor neuron specific 
expression pattern of miR-218 in ventral motor neurons throughout the human spinal cord 
(Fig. 1A). In parallel, we differentiated human inducible pluripotent stem cells (iPSCs) into 
motor neurons, following a protocol developed by Kiskinis et al. (19). Accordingly, several 
mRNA markers of motor neuron differentiation were upregulated, namely, Isl1, Hb9 and 
ChAT. miR-218 expression was upregulated >2000 fold from undifferentiated pluripotent 
state to human motor neurons (Fig. 1B). We then assessed miR-218 expression in laser 
capture microdissection motor neurons from lumbar spinal cords of samples where 
neurological disease was not reported, by revisiting data that was generated in our previous 
work (3). miR-218 is specifically enriched in control motor neurons relative to surrounding 
non motor neuron tissue at the ventral horn of the human lumbar spinal cord or relative to 
SURSULRFHSWLYHQHXURQVDW&ODUNH¶VFROXPQ)XUWKHUPRUHDVVHVVLQJPL5-218 expression in 
laser capture microdissection-enriched surviving lumbar motor neurons of patients with 
ALS that suffered from bulbar onset disease, revealed ~2 fold repression relative to control 
lumbar motor neurons (Fig. 1C and Datafile S1). We further tested another independent set 
of postmortem tissues with an orthogonal nanoString nCounter miRNA profiler. This RNA 
study revealed that miR-218 was the most downregulated miRNA in lumbar ventral horns 
of sporadic ALS (sALS) nervous systems, relative to nonǦneurodegeneration controls (Fig. 
1D and Datafile S2). Reduced miR-218 in ALS may be explained by loss of motor neurons 
and / or by molecular downregulation in motor neurons that are still present in the ventral 
horn. Accordingly, we have performed miR-218 in situ hybridization that revealed reduced 
numbers of miR-218+ cells in ALS patient tissue relative to nonǦneurodegeneration 
controls (Fig. 1E and Datafile S1) and a reduction in the densitometric miR-218 in situ 
hybridization signal in ALS motor neurons (Fig. 1F). Finally, we demonstrated that there 
is a global upregulation (de-repression) of miR-218-5p targets in human ALS spinal motor 
neurons by comparing the expression of top 100 predicted miR-218-5p mRNA targets 
(TargetScan (20)), in laser capture microdissection-enriched surviving motor neurons from 
lumbar spinal cords of patients with sALS relative to all expressed mRNAs and to the 
expression in non-neurodegeneration controls (Fig. 1G (21)). Taken together, our results 
show that miR-218 is a highly sensitive marker of human spinal motor neurons, whose 
expression rises high in developing human motor neuron and is maintained in the adult. 
miR-218 expression is reduced in motor neuron disease because of both molecular 
downregulation and of motor neuron loss and the mRNA targets of miR-218 are 
reciprocally upregulated. Therefore, miR-218 might serve as marker of motor neuron mass 
in the human ventral horn in ALS.  
miR-218 regulates motor neuron network activity 
To study miR-218 function, we moved to rodent models, whereby miR-218 is specifically 
expressed in mouse motor neurons, without any preference to motor neuron subtypes (Fig. 
S1 and (1, 2)). We first performed ontology analysis (22) of predicted miR-218 targets 
(20). This study identified enrichment in biological processes related to potassium ion 
transmembrane transport (Fig. 2A). Therefore, we tested the hypothesis that miR-218 
regulates primary motor neuron gene expression and activity. Dissociated embryonic 
mouse spinal cords, were enriched for motor neurons via optiprep gradient sedimentation 
(23) and transduced with lentiviruses encoding miR-218 overexpression (OE) or miR-218 
knockdown (KD). Next generation sequencing (NGS) of RNA revealed that predicted 
miR-218 targets (TargetScan (20)), were significantly down-regulated following OE of 
miR-218 (Fig. 2B, p<0.0001). Accordingly, enrichment for two miR-218-5p seed-matches 
was depicted among mRNAs that were down / up regulated following miR-218 OE / KD, 
respectively (Sylamer study (24), Fig. 2C,D). No signatures were identified for the target 
set of any other miRNA. Therefore, the vectors used were specifically affecting miR-218 
expression or silencing functions. Expression data are available at gene expression 
Omnibus (GSE136409). 
We then monitored intracellular calcium transients in primary rat motor neurons that 
overexpressed (~8-fold), or knocked-down (~50%) miR-218. Calcium dynamics were 
monitored on days 12-13 in vitro, using the Ca2+-sensitive dye, Fluo2 HighAff AM, setting 
the spike threshold for activity as delta F / F > 2 over baseline (Fig. 2E,F). miR-218 OE 
increased the frequency of spontaneous calcium bursts by ~70%, compared to cells that 
were transduced with control viruses, whereas miR-218 KD attenuated neuronal Ca2+ 
transient by ~80%, relative to control (Fig. 2G,H). Changes in miR-218 expression did not 
alter motor neuron viability or morphology (Fig. S2). Therefore, miR-218 regulates 
neuronal activity.  
miR-218 regulates neuronal intrinsic excitability  
To test if miR-218 is involved in the regulation of active or passive conductance in neurons, 
we further employed patch-clamp. However, since primary motor neurons displayed an 
elevated resting membrane potential of >-50mV in our hands, consistent with a previous 
study (25), we were forced to use primary rat hippocampal neurons as alternative, a well-
established cell type for patch clamp studies, which expresses miR-218, though less than 
spinal motor neurons (26-28). Current clamp electrophysiological experiments were 
performed with CNQX (6-cyano-7-nitroquinoxaline-2,3-dione, AMPA/Kainate blocker) 
and APV (2-amino-5-phosphonopentanoate, NMDA receptor blocker), on culture days 15-
21. In response to current injection (300 pA, 500ms) neuronal firing frequency was 
~twofold higher with miR-218 OE, relative to miR-218 KD (17.9 Hz ± 1.3 vs. 9.4 ± 1.9 
Hz, p<0.01, Fig. S3A,B) and rheobase, the current input required to generate an action 
potential (500ms ±100 to +500 pA steps in 20 pA increments), was ~35% lower in miR-
218 OE, relative miE-218 KD (157 ± 12 pA vs. 242 ± 19 pA, p<0.001, Fig. S3C,D). Mean 
voltage threshold for triggering the first spike was unchanged between the different 
conditions (Fig. S3E) and resting membrane potential (RMP) correlated in a bidirectional 
manner with miR-218 expression (miR-218 OE -58.8± 0.7 mV, n=65; control, -60.9±0.7 
mV, n=44; miR-218 KD -63.7 ± 0.7 mV, n=30, p-value<0.001, Fig. S3F). Taken together, 
network and intrinsic activity studies support the hypothesis that miR-218 regulates 
neuronal excitability, at least in rat hippocampal neurons.   
Kv10.1 functions downstream of miR-218 in motor neurons  
To gain molecular insight into the mechanisms by which miR-218 regulates network 
activity, we next focused on a selected set of relevant targets in the context of neuronal 
activity. This group includes the potassium channels Kv4.2 (Kcnd2) and Kv10.1 (Kcnh1), 
GABA receptor subunits Gabrb2 and Gabrg1, GABA transporter GAT1 (Slc6a1) and the 
calcium channel beta subunit Cacnb4. The changes in the expression of the above six 
targets, in response to miR-218 overexpression, were validated in an independent set of 
experiments using qPCR on RNA extracted from rat primary motor neurons (Fig. 3A).  
Because miR-218 enhances neuronal activity, we hypothesized that relevant mRNA targets 
potentially encode for proteins acting downstream of miR-218 in inhibiting neuronal 
activity. Thus, their KD should increase bursting, reminiscent of miR-218 OE, and 
concomitant KD of both miR-218 and its target may rescue neuronal activity. 
 
We therefore analyzed the frequency of spontaneous calcium transients in primary motor 
neurons following candidate target KD, with siRNA nanoparticles that exhibited 20%-80% 
target mRNA KD (Fig. S4). Non-targeting siRNAs were used as control. Knockdown of 
either Kv10.1 (Kcnh1) or Kv4.2 (Kcnd2) enhanced the frequency of spontaneous calcium 
transients and was sufficient to rescue neuronal excitation upon miR-218 inhibition (Fig. 
3B-D). In addition, we tested the calcium channel Cacnb4 and GABA pathway components 
Gabrb2, Gabrg1 and GAT1, which did not obey the requirements to be considered as 
epistatic downstream effectors of miR-218 in the motor neuron system, under our 
experimental conditions (Fig. 3E-H).  
To substantiate the evidence for the relevance of voltage-gated potassium channels, we 
performed a series of additional studies that collectively increased our confidence in the 
relevance of Kv10.1 and were not sufficiently supportive of Kv4.2 in this context.  
 
We demonstrated that both Kv10.1 (Kcnh1) or Kv4.2 (Kcnd2) mRNAs can be directly 
targeted by miR-218, by measuring the luminescence of a Renilla reporter, harboring the 
ƍ XQWUDQVODWHG UHJLRQ ƍ875) of either Kv10.1 (Kcnh1) or Kv4.2 (Kcnd2). miR-218 
silencing was abrogated by mutated miRNA recognition sequences (Fig. 3I and Fig. S5A). 
We also mined miRNA-mRNA chimera data from AGO2 cross linking and 
immunoprecipitation study in the mouse cortex (29). This study revealed miR-218 binding 
WRWKH¶875RI.Yin vivo in the unmanipulated cortex (Fig. 3J). We next transduced 
primary rat motor neurons with viral vectors that either overexpress or knockdown miR-
218 (Fig. 3K). miR-218 expression reciprocally correlated with Kv10.1 protein under miR-
218 KD (Fig. 3L, Fig. S6 and Datafile S3), as could be expected from a genuine target. 
miR-218 OE did not affect Kv10.1 expression, which might be because of the high basal 
miR-218 expression in motor neurons. Finally, to test if Kv10.1 is upregulated in ALS, 
along with miR-218 downregulation, we mined human NGS data, which revealed higher 
Kv10.1 mRNA expression in ALS, in both induced human motor neurons of patients with 
ALS ((30) Fig. 3M) and in laser capture microdissection-enriched surviving motor neurons 
from lumbar spinal cords of patients with sporadic ALS (sALS) with rostral onset and 
caudal progression ((21) Fig. 3N). A parallel analysis of Kv4.2 expression and regulation 
was not equally supportive and it is therefore less likely to be regulated by miR-218 in 
motor neurons and in ALS (Fig. S5B-F and Datafile S4). Therefore, Kv10.1 appear as a 
relevant miR-218 target in vitro and in vivo and might be relevant also in human ALS. 
Rare miR-218 genetic variants are detected in human patients with ALS 
To examine the relevance of miR-218 to human disease we screened for rare genetic 
variations (minor allele frequency <0.01) in the human miR-218-1 (Chr. 4) and miR-218-
2 (Chr. 5) genes in ALS and controls cohorts of Project MinE ALS sequencing consortium 
data (31). We observed 6 unique rare variants in the precursor miR-218-2 (pre-miR-218-
2) gene and a single variant (rs371622197) in pre-miR-218-1 (Fig. 4A and table S1) in 
multi-national cohorts, which were matched geographically and for ancestry (see methods). 
None of these variants were harbored within the ~22 nucleotides of mature miR-218-5p 
[miRBase v20 (32)]. Region-based rare variant association testing by the Optimized 
Sequence Kernel Association Test (SKAT-O) (33) was non-significant (adjusted p value 
>0.05). However, odds ratio (OR) was 1.93 with 95% confident interval (CI): 0.42-8.96 
(Fig. 4B). We then performed an independent replication study on additional cohorts of 
Genomic Translation for ALS Care (GTAC), the ALS Sequencing Consortium and the 
New York Genome Center (NYGC) ALS Consortium for rare miR-218-2 variant 
association.  
Rare miR-218-2 variants were enriched in cases (p = 0.048 by SKAT-O; OR=3.06, 95% 
CI: 0.86 - 10.84). Meta-analysis of both discovery and replication cohorts p value was 
0.067 by SKAT-O, (34) DQGDMRLQWDQDO\VLVSYDOXHZDV&KLVTXDUHGZLWK<DWH¶V
correction; OR=2.87, 95% CI: 1.11-7.40; Fig. 4B). Therefore, the burden of variants 
showed nominal association to the trait (p(?(? DOWKRXJK LWGLGQRW UHDFKgenome-
wide significance (p(? (?(?î(?í) with ALS in our study. Finally, we assessed an 
independent large cohort of 62,784 non-ALS genomes from NHLBI's Trans-Omics for 
Precision Medicine (TOPMed). This validation effort yielded a joint p value of 0.0002 by 
Chi-6TXDUH WHVW ZLWK <DWH¶V FRUUHFWLRQ ZLWK 25   &,  - 5.52), which 
confirmed the robustness of the findings (Fig. 4B). This modest excess of rare pre-miR-
218-2 variants in ALS did not survive genome wide statistical correction. Taken together, 
individuals harboring miR-218-2 sequence variants have a risk that is almost three time as 
high to suffer from ALS, relative to the general population.  
 
Rare miR-218 genetic variants disrupt its ability to regulate neuronal excitability  
miRNA genes exhibit high evolutionary conservation and sequence mutations may be 
detrimental to their function. We sought to test the impact of mutated miR-218 on neuronal 
activity by intracellular calcium transient recording. The variants were aggregated in two 
main domains, namely in the loop region, that is supposed to bind DGCR8 (35) and in the 
miRNA 3' terminal, which is cleaved by Drosha (35, 36) and then becomes an important 
element of recognition by Dicer (37, 38). To test these variants functionally, we created 
vectors that represent loop and 3' terminal variants. Then, we transduced primary rat motor 
neurons with the following miR-218-2 vectors: (i) Control vector, (ii) wild-type human 
miR-218-2 (WT); (iii) the predominant pre-miRNA loop variant (Chr5:168,195,207, V2); 
(iv) the most abundant patient variant at the miRNA 3' terminal (Chr5:168,195,174, V5); 
(v) a miR-218-2 version, harboring a collection of variants, superimposed from cases (Vall); 
or (vi) a miR-218-2 sequence that we designed to be resistant to Drosha activity, which 
yields no mature miR-218 (Vdead). Wild-type miR-218 increased spontaneous calcium burst 
frequency as expected, whereas miR-218 with variant sequences failed to upregulate 
neuronal Ca2+ transient frequency (Fig. 4C,D).   
Rare miR-218 genetic variants inhibit its biogenesis  
We tested the hypothesis that miR-218 variants impair neuronal bursting, through 
inhibition of biogenesis or creation of abnormal forms of the mature miRNA. We used 
HEPG2 cells, which do not express the endogenous miR-218 gene, to over express wild-
type or mutated forms of primary miR-218 (pri-miR-218). In addition, we co-transfected 
miR-214-3p mimics, which served as spike-in control for downstream normalization.  
We performed small RNA NGS, on RNA extracted from transfected HEPG2 cells (Fig. 
5A). miRNAs were the dominant RNAs in the libraries (56%, Fig. 5B), at approximately 
a million miRNA reads / library and complexity of ~160 different miRNA species (Fig. 
5C). The expression of mature miR-218 following transfection was comparable with the 
most abundant endogenous miRNAs in HepG2 cells (Fig. 5D). miR-218-5p dominated the 
expression profile, whereas sequences aligned to the loop or to miR-218-3p were less 
prevalent, as expected (Fig. 5E). Furthermore, the isomiR-218 profile was comparable 
across different variants (Fig. 5F). The expression of mature miR-218, derived from 
mutated forms of pri-miR-218, was lower compared to the wild-type form (Fig. 5G). We 
validated the drop in mature miR-218 expression, when harboring variants, with 
quantitative real time PCR (Fig. 5H). We also detected the accumulation of pre-miR-218 
forms, following transfection with a vector harboring the most abundant variant (V5; Fig. 
5I), a hallmark of failed biogenesis. The inhibition score (3), describing the ratio of DICER 
substrate (pre-miR-218) to product (mature miR-218), was increased by 3.4 fold for the 
predominant pre-miRNA loop variant (V2) and by 3.1 fold for the most abundant variant 
(V5), relative to wild-type miR-218, demonstrating inhibition of miR-218 biogenesis 
(Fig. 5J). Taken together, mutated miR-218 exhibits impaired biogenesis, providing a 
conceivable mechanism for insufficient regulation of neuronal activity.  
Discussion  
miR-218 was recently put in the spotlight for its roles in motor neuron development (1, 2). 
The link between perinatal death of mice deficient of miR-218 and a potential deleterious 
effect in adult humans requires further investigations. In the current work, we demonstrated 
miR-218 relevance to human motor neurons in a systematic effort that explains how miR-
218 contributes to a previously unappreciated facet of motor neuron specificity and disease 
susceptibility. ALS neuropathology establishes miR-218 as marker of human motor neuron 
mass and well-being that is downregulated in ALS. Accordingly, mRNA targets of miR-
218 are upregulated / de-repressed.  
We identified rare sequence variants in the miR-218-2 gene that impair miR-218 
biogenesis and its ability to regulate motor neuron activity. These sequence variants are 
relevant for the understanding of motor neuron health and disease. We suggest that miR-
218-2 variants are sub-optimal for a Dicer-dependent step of biogenesis, thus reducing 
mature miR-218 expression and contributing to selective motor neuron vulnerability. 
Subtle miR-218 downregulation in humans, plausibly contributes to failed homeostasis in 
adults, potentially because of broad upregulation (de-repression) of dozens of miR-218 
targets in human motor neurons. Furthermore, because miR-218 expression is 
downregulated in motor neurons of sporadic and familial patients with ALS, individuals 
harboring miR-218 variants suffer two sequential hits to miR-218 expression and function. 
Therefore, miR-218 is a relevant candidate for genetic screening in additional ALS genetics 
cohort. 
A previously unrecognized pathway downstream of miR-218 controls neuronal activity by 
regulating the voltage-gated potassium channel, Kv10.1. Altered motor neuron excitability 
and ion channel dysfunction have been reported in patients, rodent and ALS iPSC models 
(39-51) and drugs such as ezogabine (retigabine) (52), or riluzole, which control potassium 
and sodium channels, respectively, elute to the relevance of therapeutically altering 
neuronal activity in ALS.  
Additionally, increased expression of voltage-gated potassium channel subtypes have been 
reported in iPSC-derived ALS motor neurons with FUS and SOD1 mutations and targeting 
potassium currents with 4-Aminopyridine, a potassium channel blocker, recovered 
neuronal activity patterns in culture (53). These observations resonate with miR-218 
activity upstream of voltage gated potassium channel and suggest that aberrant neuronal 
activity is an important contributing factor at the ALS milieu.  
Our study does not rule out that additional targets may play parallel roles in controlling 
neuron activity downstream of miR-218. miR-218 is a member of an expanding class of 
miRNAs that regulate neuronal activity in flies (54, 55) and mammals (56-59), including 
miR-128 (57), miR-101 (28) and miR-324-5p (60). The emerging regulation of neuronal 
activity by miRNAs depends on their capacity to fine-tune the expression of dosage-
sensitive proteins locally, at dendrites, axons and synapses.  
miR-218 regulates a myriad of targets designated Target218 (1). Our work, along with 
reported specific targets in astrocytes and neuronal progenitors (2, 5), contribute to 
deconvoluting the Target218 network. Interestingly, Amin et al. recently showed by a patch 
clamp study in lumbar spinal slices that miR-218 contributes to inhibiting neuronal activity 
(1). Reconciling this observation with ours requires new conditional miR-218 alleles that 
will allow uncoupling miR-218 roles in interneuron differentiation (2) and plausibly in 
establishing interneuron-motor neuron circuitry, from miR-218 roles in adult motor 
neurons. Furthermore, developmental loss of miR-218 causes motor neuron death, further 
complicating the comparison to the moderate KD in the post-mitotic motor neurons.  
In summary, motor-neuron enriched miR-218 might serve as a marker of motor neuron 
mass in the human ventral horn in ALS and miR-218 functions uncovers previously 
unappreciated facets of motor neuron specificity that may be particularly susceptible to 
failure in human patients with ALS. Currently, it is not clear if the global miR-218 
downregulation in human neuropathology is a consequence of Dicer inhibition (3) and how 
such a downregulation might impact non-cell autonomous effects of miR-218 (5). Mouse 
modelling can be beneficial for exploring miR-218 allele genetic interactions with other 
ALS-associated mutations and the functional implications of the discovered variants in the 
miR-218-2 gene sequence. Therefore, the study contributes to an emerging view of ALS 
as a disease with a prominent RNA component and suggests that miR-218 is a potential 
therapeutic target for motor neuron disease (graphically summarized in Fig. S7). 
Materials and Methods 
Study design 
The overall objective of our study was to investigate the relevance of motor-neuron specific 
miR-218 to human motor neuron specificity and disease (summary in Fig. S7), by 
employing molecular, neurogenetics and neuropathology approaches. First, we performed 
four orthogonal miRNA quantification studies in human motor neurons: (1) chromogenic 
miR-218 in situ hybridization in human spinal cord, (2) nanoString nCounter, (3) miR-218 
qPCR, and (4) analysis of mRNA expression of miR-218 targets from laser capture 
microdissection-enriched surviving motor neurons from lumbar spinal cords of patients 
with sALS. These experiments established miR-218 as marker of human motor neuron 
mass and well-being. To test whether miR-218 regulates motor neuron activity we 
transduced primary motor neuron with lentiviruses encoding miR-218 OE or KD and 
monitored intracellular calcium transients and intrinsic activity by patch-clamp 
electrophysiological experiments. A series of bioinformatics and experimental steps 
collectively directed us to conclude that Kv10.1 is a direct target of miR-218 in this system. 
Using statistical genetics and burden studies of rare variants, we identified miR-218 genetic 
variants in large ALS cohorts. The variants were shown to inhibit biogenesis and to impair 
miR-218 function. Experimentalists were blinded while analyzing data. Outliers were 
excluded if deviated ±2 SDs away from mean. The number of samples that were taken for 
case-control cohort in neuropathology (Human motor neuron systems: 20 ALS cases, 14 
nonǦneurodegeneration controls) and neurogenetics (Human genomes: 7,738 ALS, 71,656 
controls). These numbers reflect the maximal availability at the time of the study. 
Statistical analysis  
Statistics performed with Prism Origin (GraphPad Software Inc.). Shapiro-Wilk test was 
used to assess normality of the data. Pair-wise comparisons passing normality test were 
DQDO\]HG ZLWK 6WXGHQW¶V W-test whereas the Mann-Whitney test was used for pairwise 
comparison of nonparametric data. Multiple group comparisons passing normality test 
were analyzed using ANOVA with post hoc tests, whereas nonparametric multiple group 
comparisons were analyzed using the Kruskal-:DOOLV WHVWZLWK'XQQ¶VSRVWKRF WHVWLQJ
when ANOVA assumptions were not met. Statistical P values <0.05 were considered 
significant. Data presented as specified in the figure legends. Data are shown as means ± 
SEM or SD or graphed using boxplots, as noted in the text. Individual subject level data 
are reported in Datafile S1.  
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Fig. 1. miR-218 is expressed in the human spinal motor neurons and is downregulated 
in human ALS. (A-F) Three orthogonal miRNA quantification studies in human 
motor neurons from 20 ALS cases and 14 nonǦneurodegeneration controls: (A) 
miR-218 chromogenic in situ hybridization depicting broad expression along the 
cervical, thoracic and lumbar regions of the adult human spinal cord. (B) qPCR 
analysis of miR-218, Hb9, Isl1 and ChAT in human iPSCs and differentiated motor 
neurons. miR-218 normalized to U6 expression. mRNAs normalized to average of 
+357DQGȕ±actin expression, presented on a log scale; n=3 independent wells per 
time point. (C) miR-218 expression in laser-capture micro-dissected human lumbar 
motor neurons. miR-218 expression in nonǦneurodegeneration motor neurons (n=7 
human spinal cords), relative to surrounding non-motor neuron anterior horn tissue 
(n=10), to Clarke¶VFROXPQSURSULRFHSWLYHQHXURQVQ RUWR$/6PRWRUneurons 
(n=9 sporadic and 2 familial nervous systems carrying the SOD1 A4V mutation). 
TaqMan qPCR analysis of miR-218 normalized to the average of 
RNU48/SNORD48, RNU44/SNORD44 and U6 in the same sample, and to the 
average miR-218 expression in the anterior horn. One-way ANOVA followed by 
Newman-Keuls multiple comparison test performed on log-transformed data, 
Means ± SD. (D) Volcano plot of relative miRNA expression in ALS lumbar 
ventral horns (n=5), versus nonǦneurodegeneration controls (n=2; xǦaxis log2 
scale), screened by nanoString nCounter platform. y-axis depicts the differential 
expression pǦvalues (-log10 scale). Black dots indicate P < 0.05; light gray dots are 
nonǦsignificant. miR-218 is the most downregulated miRNA in ALS nervous 
systems. Data normalized to the average of five control mRNAs (ACTB, B2M, 
GAPDH, RPL19, RPLP0). (E) Reduced miR-218+ cell numbers in sALS patient 
anterior horns (n=4), relative to nonǦneurodegeneration controls (n=5) and 
representative miRNA in situ hybridization micrographs. Two way ANOVA 
followed by %RQIHUURQL¶V PXOWLSOH FRPSDULVRQ test, Means ± SEM, and (F) 
chromogenic miR-218 in situ hybridization signal densitometry in motor neurons 
at different spinal cord levels (nonǦneurodegeneration control/ALS cases: Cervical 
n=151/85 cells; Thoracic n=54/75; Lumbar 189/92). One-tailed Mann-Whitney 
test, Means ± SEM. (G) Cumulative distribution function (CDF) plot of top 100 
predicted miR-218-5p targets (TargetScan (20)), or all expressed mRNAs, in laser 
capture microdissection-enriched surviving motor neurons from lumbar spinal 
cords of patients with sALS with rostral onset and caudal progression (n=13) 
relative to non-neurodegeneration controls (n=6; (21)) and Box-Plot (inset) 
depicting median, upper and lower quartiles and extreme points. P-value calculated 
using Kolmogorov±Smirnov test comparing miR-218-5p targets subset distribution 
to all genes. * P<0.05; *** P<0.001; **** P<0.0001.  
Fig. 2. miR-218 controls motor neuron network activity. (A) Seven most enriched gene 
ontology terms (22) of predicted miR-218 targets (20). p-value of term enrichment 
(±log10, dashed orange line indicates P = 0.05). (B) CDF plot of miR-218 predicted 
targets, relative to all expressed mRNAs, following OE of miR-218 and box-plot 
(insets), depicting median, upper and lower quartiles and extreme points. P-value 
calculated using Kolmogorov±Smirnov test comparing miR-218-5p subset 
distribution to all genes. **** P<0.0001. Binding site enrichment of all known 
miRNAs, in ~10,000 expressed mRNAs, was tested after (C) miR-218 OE, or (D) 
miR-218 KD, relative to control virus. Significant enrichment for two miR-218-5p 
seed-matches (blue, red) and lack of enrichment for any other miRNA (gray) via a 
Sylamer study (24). (E) Diagram of calcium transient imaging in embryonic rat 
spinal motor neurons, transduced with lentiviruses encoding control vector, miR-
218 OE or a miR-218 KD. Neuron time lapse micrographs (F), representative traces 
(G) and (H) quantification of spontaneous calcium spike frequencies (¨))! 
from Fluo2 HighAff AM study after 12 days in vitro. Recorded from 58 / 76 / 41 
control / OE /KD cells, respectively. Box-Plot depicting the median, upper and 
lower quartiles and extreme points. Kruskal-:DOOLV WHVW IROORZHG E\ 'XQQ¶V
multiple comparison test, *** P<0.001. This experiment was repeated 3 
independent times with similar results.  
Fig. 3. The potassium channel Kv10.1 acts downstream of miR-218. (A) qPCR 
measuring the expression of mRNAs targets, following miR-218 OE (n=15). Data 
normalized to control virus (n=12) and to average expression RI+357DQGȕ±actin, 
two technical duplicates, two-VLGHG VWXGHQW¶V t-test, Means ± SEM. (B) 
Representative traces of individual motor neurons and (C-H) quantification of 
spontaneous calcium spike frequencies (¨))!of embryonic rat spinal motor 
neurons, transduced with lentiviruses encoding a control vector or miR-218 KD 
and further transfected with siRNA for specific target KD or a non-targeting siRNA 
FRQWURO PLQXV VLJQ  FHOOV UHFRUGHG SHU HDFK H[SHULPHQWDO FRQGLWLRQ 1
independent experimental repeats with similar results. Kruskal-Wallis test followed 
E\'XQQ¶VPXOWLSOHFRPSDULVRQWHVWI) Relative Renilla luminescence upstream of 
a wild-W\SH .Y ƍ875 RU D PXWDWHG ƍ875 WKDW LV LQVHQVLWLYH WR PL5-218, 
normalized to co-expressed firefly luciferase and to a negative control miRNA 
vector. n=3 independent wells per experimental condition. One-way ANOVA 
IROORZHG E\ %RQIHUURQLH¶V PXOWLSOH FRPSDULVRQ WHVW 0HDQV  6(0 (J) miR-
218:Kv10.1 ¶875FKLPHUDIURPDQ$*2&/($5-CLIP experiment in mouse 
cortex (29). (K) miR-218 expression (qPCR n=3, normalized to U6) and (L) 
Kv10.1 protein expression (Western blot n =5), upon miR-218 lentiviral KD or OE, 
in primary rat motor neurons and a representative blot detected with anti Kv10.1 
and anti Tubulin Beta-III (TUBB3) antibodies. Box-Plots depict median, upper / 
lower quartiles & extreme points, one-way ANOVA followed by Newman-Keuls 
multiple comparison test. (M) Kv10.1 mRNA expression, as log2 normalized 
counts, from NGS study of induced ALS motor neurons (n=4 different donors in 
duplicates) or non-neurodegeneration controls (n=3 different donors in duplicates; 
(30)). Box-Plots depict median, upper / lower quartiles & extreme points, DESeq 
analysis. (N) Kv10.1 mRNA expression, as Reads Per Kilobase Million (RPKM) 
from NGS study of laser capture microdissection-enriched surviving motor neurons 
from lumbar spinal cords of patients with sALS with rostral onset and caudal 
progression (n=12) and non-neurodegeneration controls (n=8; (21), GSE76220). 
Box-Plots depict median, upper / lower quartiles & extreme points, two-sided 
VWXGHQW¶Vt-test. * P<0.05; ** P<0.01; *** P<0.001; ns ± non-significant. 
  
Fig. 4. Rare genetic miR-218 variants disrupt its ability to regulate neuronal activity. 
(A) Diagrams of miR-218-2 pri-miRNA (upper) and the pre-miRNA hairpin 
(lower), with demarcation of DROSHA, DGCR8 and DICER binding and arrows, 
revealing variant nucleotides (V1-V6). Guide RNA in red. (B) Table and forest plot 
depicting odds ratio (OR) estimates with 95% confidence intervals (CI), across 
study cohorts and p-values, calculated with SKAT-O or Chi-squared test with 
<DWH¶V FRUUHFWLRQ 9HUWLFDO GRWWHG OLQH GHQRWHV 25  C) Representative motor 
neuron traces and (D) quantification of spontaneous calcium spike frequencies 
(¨))! in embryonic rat spinal motor neurons, transduced with lentiviruses 
encoding WT or mutated human miR-218-2. Number of cells recorded in a single 
experiment: Control, n=131; WT miR-218-2, n=114; single variant V2, n=137; 
single variant V5, n=119; multiple variant Vall, n=118; Unprocessable miR-218-2 
Vdead, n=111. N=4 independent times with similar results. Kruskal-Wallis test 
IROORZHGE\'XQQ¶VPXOWLSOHFRPSDULVRQWHVW*** P<0.001; ns ± non-significant.  
Fig. 5. Rare genetic variants in miR-218 inhibit biogenesis. (A) Diagram of 
experimental design. HEPG2 cells transfected with WT miR-218-2 or miR-218-2 
genetic variants and processing of RNA for NGS and qPCR studies. (B) Pie chart 
of relative representation of different RNA families in NGS data (percentage of 
reads aligned to miRNA- 56%; tRNA -20%; rRNA ± 13%; other RNA types ± 
11%). (C) The number of expressed miRNAs was comparable across samples. 
Means ± SEM. (D) MA plot of miRNA expression in HEPG2 cells transfected with 
wild-type miR-218-2, relative to control vector. Abundance (x-axis; presented on a 
log scale) against ratio of miRNA in cells overexpressing WT miR-218 vs a control 
vector (log 2 fold change). (E) Histogram of number of reads-per-base for WT miR-
218-2 sequences, aligned over the genomic sequence. (F) Bar graph of miR-218-2-
5p isotypes (isomiR-218-2-5p, sequence denoted) in HEPG2 transfected with WT 
miR-218-2, or V2 / V5 variants. Relative expression of mature miR-218-2 from (G) 
NGS or (H) TaqMan qPCR studies, normalized to miR-214-3p spike-in mimics. 
(I) Pre-miR-218-2 expression from NGS. (J) The ratio of pre-miR-218-2 
(substrate) to mature miR-SURGXFWGHILQHGDV³LQKLELWLRQVFRUH´,QKLELWLRQ
score approximates a value of 1 in the WT condition, whereas a value > 1, reflects 
reduced DICER activity. Control, n=3; WT miR-218-2, n=5; single variant V2, 
n=4; single variant V5, n=4; multiple variant Vall, n=5; Unprocessable miR-218-2; 
Vdead, n=3. Box-Plots depict median, upper / lower quartiles & extreme points, One-
way ANOVA IROORZHG E\ %RQIHUURQL¶V PXOWLSOH FRPSDULVRQ WHVW SHUIRUPHG RQ 
data (I) or log-transformed data (G, H, J), * P<0.05; ** P<0.01; *** P<0.001; ns 
± non-significant. 
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Materials and Methods 
Ethical approval of studies  
All subjects contributed DNA for genetic studies approved by local IRBs at the 
submitting sites. Human materials were studied under approval of Institutional review 
boards at U.C. San Diego and Weizmann Institute of Science Institutional Review Board. 
miRNA analysis was performed as previously described (3). All animal experiments were 
approved by Weizmann Institute of Science IACUC (protocols 33230117-2; 24390116-2; 
32271216-1; 23690116-1; 23660116-2; 07201113-1; 02170413-2; 07811212-2). 
Human genetics  
Project MinE ALS sequencing consortium (31), comprises of seven independent cohorts: 
the Netherlands, Belgium, Ireland, Spain, United Kingdom, United States and Turkey, 
served as a discovery cohort. Whole-genome sequencing (WGS) of 6,579 samples was 
performed on Illumina HiSeq2000 or HiSeqX platforms. Reads were aligned to human 
genome build hg19 and sequence variants called with Isaac Genome Alignment Software 
and variant caller (61). Individual genomic variant call format files (GVCFs) were merged 
ZLWKµDJJ¶WRRODXWLOLW\IRUDJJUHJDWLQJ,OOXPLQD-style GVCFs. Multi-allelic variants were 
excluded from analyses. Following completion of the raw data merge, multiple quality 
control (QC) filtering steps were performed: (i) setting genotypes with GQ<10 to missing; 
(ii) removing low-quality sites (QUAL< 30 and QUAL< 20 for SNPs and indels, 
respectively); (iii) removing sites with missingness > 10%. (iv) Samples excluded if 
deviated from mean by more than 6SD for total numbers of SNPs, singletons and indels, 
Ti/Tv ratio, het/hom-non-ref ratio and inbreeding (by cohort). (v) missingness > 5%, (vi) 
genotyping-sequence concordance (made possible by genotyping data generated on the 
  
Illumina Omni 2.5M SNP array for all samples; 96% concordance), (vii) depth of coverage, 
(viii) a gender check (to identify mismatches), (ix) relatedness (drop samples with >100 
relatedness pairs). Related individuals were further excluded until no pair of samples had 
a kinship coefficient > 0.05). (x) missing phenotype information. A total of 6119 samples 
(4281 ALS cases and 1838 healthy controls) passed all QC and were included in 
downstream analysis. Per-nucleotide site QC was performed on QC-passing samples only, 
for biallelic sites: variants were excluded from analysis based on depth (total DP < 10,000 
or > 226,000), missingness > 5%, passing rate in the whole dataset < 70%, sites out of 
Hardy±Weinberg equilibrium (HWE; by cohort, controls only, p < 1x10-6) and sites with 
extreme differential missingness between cases and control samples (overall and by cohort, 
p < 1x10-6). Depth of coverage for all miR-218 variants was >25x.  
BED file containing genomic coordinates for miR-218-1,2 precursors (according to 
miRBase v20 (32)) on human genome build 19 (hg19), Chr5:168195173-168195236; 
Chr4: 20529922-20529986, was created and variants in these regions were than extracted 
from the whole-genome sequencing data using vcftools (62). A replication study comprised 
of data from the Genomic Translation for ALS Care (GTAC), the ALS Sequencing 
Consortium and the New York Genome Center (NYGC) ALS Consortium genomes and 
exomes from ALS cases (5336) and non-ALS controls (21388). QC filtering steps were: 
(i) setting genotypes with GQ<10 to missing; (ii) removing low-quality sites (QUAL) < 30 
for SNPs; (iii) removing sites with missingness > 10%; (iv) depth of coverage >10x with 
>85% of bases in the miR-218-2; (v) a gender check (to identify mismatches); (vi) related 
individuals by kinship (3 degrees); (vii) missing phenotype information; (viii) ancestry 
harmonization with iterative EIGENSTRAT cycles. Samples excluded if deviated from 
  
mean by more than 1SD for the first 4 principal components. Finally, 22 samples 
overlapping with Project Mine dataset were excluded by KING (63). A total of 10,491 
samples (3457 ALS cases and 7034 healthy controls) passed all QC. Pass filter rare biallelic 
variants were included for downstream analyses, tested for Hardy±Weinberg equilibrium 
and for extreme differential missingness between cases and control samples (overall p < 
1x10-6). 
To further increase sample size, as part of a validation effort, we harvested rare biallelic 
miR-218-2 variants from 62,784 non-ALS genomes that were available to us through 
NHLBI's Trans-Omics for Precision Medicine (TOPMed) program.  
Association of rare variants, in cases versus controls, in pre-miR-218 genomic region, was 
evaluated by SKAT-O using 'SKAT' R package (33) with sex and the top 10 PCs as 
covariates for Project MinE discovery cohort and with sex, platform and the top 3 PCs for 
replication study. Summary statistics from each study cohort was used to carry out region-
based rare variant meta-analysis, by SKAT-O using 'MetaSKAT' R package (34).  
TOPMed covariates information is not available, therefore, joint analysis was used, by one 
WDLOHG&KLVTXDUHWHVWZLWK<DWH¶VFRUUHFWLRQLQVWHDGRI a meta-analysis. We considered a 
variant to be rare if the minor allele frequency (MAF) <0.01. 
Immortalized cell lines and transfection  
Human embryonic kidney 293T (HEK293T) and HEPG2 cell lines were maintained in 
Dulbecco's modified Eagle's Medium (DMEM) supplemented with 10% FBS, 1% L-
glutamine and 1% Penicillin-streptomycin (Biological industries) at 37 °C with 5% 
CO2 incubation. Cells were seeded onto 24-well plates (Corning) 24 h prior to transfection, 
  
in antibiotic- free media and transfected at 70±80% confluence, using Lipofectamine 2000 
(Life Technologies) with 800 ng plasmid DNA per 1/24-well plate. For small RNA next 
generation sequencing (NGS), cells were co-transfected using 1 nM miR-214-3p 
microRNA mimic (Integrated DNA Technologies, Inc., table S2). Each well was 
considered as a single technical replicate. 
Neuronal cultures  
C2 hiPSCs were kindly provided by Dr. Jacob Hanna (Weizmann Institute of Science), 
cultured and differentiated as previously described (19). Mixed populations of motor 
neurons were gained, with moderate (30-50% motor neuron enrichment). Primary motor 
neurons were isolated and cultured as previously described (23). Briefly, Sprague-Dawley 
timed-pregnant females were sacrificed at rat embryonic day 14.5 (E14.5), and spinal cords 
were dissected and dissociated enzymatically with papain (2mg/ml, Sigma). Motor neurons 
were separated over a gradient of Optiprep (Sigma) and plated on 13mm coverslips 
(200,000 cells/ coverslip, Thermo scientific), pre-coated with 3µg/ml poly-ornithine 
(Sigma) and 3µg/ml laminin (Gibco). Motor neurons were cultured with Neurobasal 
medium (Gibco) supplemented with 2% B27 (Gibco) 2% horse serum (Sigma), X1 
Glutamax (Gibco) and 1ng/ml CNTF and GDNF (Peprotech). To inhibit glial overgrowth, 
ȝ0IOXRURGHR[\XULGLQH6LJPDZDVDGGHGDIWHUGD\VRI in vitro culture (DIV). For 
RNAseq analysis, primary motor neurons were isolated from time pregnant C57BL/6 mice 
at embryonic day 13.5 (E13.5). Primary cultured hippocampal neurons were prepared from 
male and female P0 Sprague-Dawley rat pups (Envigo). CA1 and CA3 were isolated, 
digested with 0.4 mg mlí papain (Worthington) and plated onto glass coverslips 
percolated with 1:30 Matrigel (Corning). Cultured neurons were maintained in a 5% 
  
CO2 humidified incubator with Neurobasal A medium (Invitrogen) containing 1.25% FBS 
(Biological Industries), 4% B-27 supplement (Gibco) and 2 mM Glutamax (Gibco) and 
plated on coverslips in a 24-well plate at a density of 65,000 cells per well. To inhibit glial 
RYHUJURZWKȝ0IOXRURGHR[\XULGLQH 6LJPDZDVDGGHGDIWHU',9 siRNAs were 
GHVLJQHGDVHLWKHUVLQJOHFKHPLFDOO\PRGLILHG¶20H'VL51$PROHFXOHVRUas pools of 
20 unmodified DsiRNA molecules (Integrated DNA Technologies, Inc., table S2). Non-
targeting scramble DsiRNAs were used as control (NC5). siRNAs were encapsulated in 
Neuro9 nanoparticles (Precision NanoSystems, Inc.) (64). Primary motor neurons were 
WUDQVIHFWHGZLWKVL51$DWDILQDOFRQFHQWUDWLRQRIȝJPORQ',96HTXHQFHVDUHOLVWHG
in table S2.  
Whole-cell patch clamp recordings  
Recordings were performed under QImaging QIClick-R-F-M-12 CCD camera in a 
chamber perfused with Tyrode's medium (150 mM NaCl, 4 mM KCl, 2 mM MgCl2, 2 mM 
CaCl2, 10 mM D-glucose, 10 mM HEPES; 320 mOsm; pH 7.35; 29 °C) at 0.5 ml / min. 
Pulled borosilicate glass pipettes (Sutter Instrument BF100-58-10) with resistances 3±5 M, 
were filled with standard intracellular current clamp recording solution (135 mM potassium 
gluconate, 4 mM KCl, 2 mM NaCl, 10 mM HEPES, 4 mM EGTA, 4 mM Mg-ATP, 0.3 
mM Na-GTP; 280 mOsm; pH 7.3). Recordings were performed using a MultiClamp 700B 
amplifier, filtered at 3 kHz and digitized at 10 kHz using a Digidata 1440A digitizer 
(Molecular Devices). Data acquired with pClamp 10 software (Molecular Devices) and 
analyzed with Matlab (Mathworks). Current clamp recordings were obtained from cells 
with over shooting action potential and a stable resting membrane potential. Each recorded 
neuron received a series of 500ms long current steps ranging from ±100 to +500 pA in 20 
  
pA increments. The current threshold for action potential was determined as the minimal 
current required for evoking an action potential during the current injection step. Spikes 
frequency was measured as the number of spikes evoked in response to 300pA current 
injection step.  
Calcium imaging  
Primary motor neurons were imaged at days 12-13 in vitro (12 DIV). Primary hippocampal 
neurons were imaged at 15 DIV. Cells plated on coverslips were incubated in 2 ȝM Fluo-
2 calcium indicator (Teflabs) for 45 minutes, in a solution containing: 129 mM NaCl, 4mM 
KCl, 1 mM MgCl2, 2mM CaCl2, 4.2mM glucose and 10mM HEPES, with pH adjusted to 
7.4 with NaOH, and osmolarity to 320 mOsm adjusted with sucrose. Cells were washed 
twice and imaged at a wave length of 488nm with a Zeiss710 confocal laser scanning 
microscope, using a 40x objective. On each coverslip, 3 fields containing at least 10 
neurons were chosen randomly for capture and analysis. At least 3 different coverslips were 
used per condition. (YHQWVLQZKLFK¨))!ZHUHLQFOXGHGLQWKHDQDO\VLV 
Retrograde labeling of neuron subtypes  
Motor neurons were back labeled via AAV-GFP injection into the mouse hindlimb 
Gastrocnemius (FF motor neurons) or Soleus (FR, S motor neurons) muscles. Mice were 
deeply anesthetized with ketamine/xylazine (0.25 mL, 10% (vol/vol), administered i.p.) 
before organ perfusion with PBS and 2.5% paraformaldehyde (PFA; as in (65)).  
miRNA in situ hybridization (ISH)  
miR-LQVLWXK\EULGL]DWLRQLQKXPDQWLVVXHVRQȝ))3(VHFWLRQVIROORZHG(66). miR-
,6+PL[SPROȝ/ in hybridization buffer (Enzo Life Sciences), was placed on 
  
tissue sections, heated to 60°C for 5 minutes and hybridizated at 37°C overnight. Sections 
were washed (0.2X SSC with 2% bovine serum albumin) at 55°C for 10 minutes, treated 
with anti-digoxigenin ± alkaline phosphatase conjugate (1:150 dilution in pH 7 Tris buffer; 
Roche) at 37°C for 30 minutes, develop with NBT/BCIP (ThermoFisher; 34042) until 
chromogen signal appeared at 15 ± 30 minutes, counterstained with nuclear fast red for 3 
to 5 minutes, rinsed and mounted with coverslips. Optical Density (OD) was calculated as 
log of (max intensity/Mean intensity). 
miR-218 in situ hybridization in mouse tissues was performed on frozen spinal cord 
sections as in (67). Slides were treated with 2µg/ml Proteinase K, fixed in EDC (Sigma), 
acetylated in acetic anhydride/ triethanolamine solution and hybridized in a hybridization 
buffer containing 40nM of 5' + 3' DIG-labeled miR-218 or scrambleLNA probe (Exiqon). 
Slides were washed, incubated with alkaline phosphatase-conjugated goat-anti-DIG Fab 
fragments (1:1000, Roche) at 4ºC overnight, developed with BCIP/NBT (Sigma), as in 
(68), mounted with Immu-mount (Shandon) and covered with a glass coverslip.  
miR-218 lentiviruses  
500bp flanking the pri-miR-218-2 sequence were purchased in pMX vectors (GeneArt, 
Invitrogen, table S3), and a 625bp fragment of the human pri-miR-218-1 were digested 
with BamHI-EcoRI and subcloned to pUltra-Hot vector (a gift from Malcolm Moore, 
Addgene plasmid # 24130) downstream of the human Ubiqiutic C promoter and mCherry-
P2A. To generate miR-218 inhibitor encoding lentivirus, an approximately 250bp fragment 
of the commercial inhibitor, miR-Zip-218 plasmid (SBI), driven by a U6 promoter was 
subcloned iQWR S*(0 YHFWRU 3URPHJD ZLWK )Z ¶- 
CGTACGTAAAGATGGCTGTGAGGGACAG-¶ DQG 5HY ¶- 
  
CGTACGTAAGAGAGACCCAGTAGAAGCAAAAAG-¶ SULPHUV DQG WKHQ LQWR WKH
¶/75 RI S8OWUD-Hot vector using a SnaBI restriction site. Lentiviral particles were 
produced in HEK-293T cells, transfected with pUltra-Hot vector and with psPAX2 and 
pMD2.G packaging plasmids (a gift from Didier Trono, Addgene plasmid numbers 12259 
and 12260). Supernatants were concentrated by ultracentrifugation, re-suspended in 
DMEM media (Gibco) and titrated. Primary neuronal cultures were infected at a 
multiplicity of infection (MOI) of 1 or of 10, on 1 DIV. 
Luciferase assays  
The rat KCND2 and KCNH1 ƍ875s were subcloned into psiCHECK2 vector (Promega) 
and transfected into HEKǦ293T cells with JETǦPEI reagent (Poly Plus) together with 
miRVec-control and miRVec-218 plasmids, that were a gift from Reuven Agami (NKI, 
The Netherlands). For each well of a 24-well plate, a 50 ng psiCHECK2 plasmid DNA and 
150 ng miRVec plasmid DNA were used; each well represents one technical replicate.72 
h postǦtransfection cells were harvested using the Dual luciferase reporter assay system 
(Promega). 
Protein analysis  
Primary motor neurons were harvested on E13.5, plated, transduced with lentivruses and 
harvested after 5 days in culture. Cell pellet lysed in (50mM Tris pH7.4, 40mM NaCl, 
1mM EDTA pH8, 0.5% TritonX-100, 50mM NaF, 10mM Na pyrophosphate, 10mM Na 
beta-glycerol phosphate, 1x phosphatase inhibitor (Roche) and 1x proteinase inhibitor 
(Roche)) and equal amounts of protein were loaded per lane for SDS-PAGE. After electro-
transfer, blots were developed with rabbit anti Kv4.2 antibody (Proteintech Group, 
Rosemont, IL catalog# 21298-1-AP, RRID:AB_10733102, 1:2000), rabbit anti Kv10.1 
  
antibody (Abcam, catalog# ab101174, RRID:AB_10862156, 1:500) and rabbit anti 
Tubulin Beta-III (TUBB3) (Biolegend, catalog# 802001, RRID:AB_2564645, 1:100,000) 
using chemiluminescence. Samples were loaded and quantified in duplicates on each gel. 
Densitometric analysis of specific bands was performed using ImageJ (NIH). 
RNA analysis  
Total RNA from cultured cells was isolated using DirectZol RNA miniprep Kit or 
miRNeasy micro Kit (Qiagen) and reverse transcribed using the miScript II RT Kit 
(Qiagen). Quantitative real-time PCR was performed with the LightCycler480 (Roche) or 
StepOnePlus (Thermo Fisher Scientific), in >3 independent biological repeats and 
technical duplicates. For miRNAs we used miScript SYBR Green PCR (Qiagen) or 
TaqMan microRNA assays (Thermo-Fisher Scientific). mRNA quantified with KAPA 
SYBR fast qPCR (KAPA biosystems). Hypoxanthine phosphoribosyltransferase 1 (Hprt) 
DQGȕ±actin were used as references for normalization of mRNA expression, and U6 for 
normalization of miRNA. Primer sequences are described in table S4. For small RNA next 
generation sequencing (NGS), cDNAs were prepared from 10 ng of total RNA using the 
4,$VHTPL51$/LEUDU\.LWDQG4,$VHTPL51$1*6 ,QGH[,/4LDJHQF'1$
libraries were pooled and sequenced on a single NextSeq 500 flow cell (Illumina), with 
75bp single read. Data was analyzed using the GeneGlobe analysis web tool (Qiagen), and 
further processed by in-house script for discovery of pre-miRNA sequences (source code: 
https://github.com/TsviyaOlender/mir-218). miR-218-5p reads were normalized to the 
reads of miR-214-3p miRNA mimic. For mRNA NGS, cDNAs were prepared following 
(69) and sequenced on one a single lane in a Hiseq2500 (Illumina) with 50bp single read. 
Fasta files for each sample were generated by the usage of Illumina CASAVA-1.8.2 
  
software. Reads for each sample were mapped independently using TopHat2 version 
(v2.0.10) (70) against the mouse genome build mm9. Approximately, 85-90% mapping 
rate was observed. Only uniquely mapped reads were used to determine the number of 
reads falling into each gene with the HTSeq-count script (0.6.1p1) (71). Differentially 
expressed genes were calculated with the DESeq2 package (v1.4.5) (72). Genes that were 
expressed at least on one sample were considered. Differentially expressed genes, were 
determined by P-adj < 0.05 and an absolute fold change >1.5. Hierarchical clustering using 
Pearson dissimilarity and complete linkage was performed in order to explore a pattern of 
gene expression. Clustering analysis was performed with Matlab software (8.0.0.783).  
NanoString 
Human spinal cord RNA was extracted using Trizol, tested by NanoDrop (Thermo 
Scientific) for O.D. of 260/280 between 1.9 - 2.1 and hybridized for 18 hrs. against the 
nCounter Human v2 miRNA Panel (798 unique human miRNA barcodes) by the nCounter 
System (NanoString Technologies). Data from 280 fields of view per sample was analyzed 
with nSolver. 
  
 
 
Fig. S1. miR-218 is highly and specifically expressed in human and murine spinal motor 
neurons. (A,C) miR-218 fluorescent in situ hybridization on transverse sections of mid-gestation 
mouse embryos (red) and (B,D) co-localization of motor neuron reporter transgene Hb9-FGP 
(green). CC-central canal; ED-ependymal layer; DRG-dorsal root ganglion; MN-motor neurons; 
S-somites. (E) In situ hybridization of pan-neuronal miR-124. Merged micrographs depict nuclei 
by DAPI counterstaining. (F) Alkaline Phosphatase chromogen development of miR-218 in situ 
hybridization on a mid-sagittal section of E13.5 mouse embryo. Arrowheads indicate the 
localization of motor neurons. miR-218 in situ hybridization on transverse hemisections of (G) 
newborn or (H) adult mouse spinal cord. Inset - large motor perikaryon cluster. (I) Transverse 
hemisections of adult mouse spinal cord, retrogradely labeled by AAV9-GFP injection into the 
lateral gastrocnemius (FF motor neurons, left) or soleus (FR/S motor neurons, right) and 
accompanied by miR-218 in situ hybridization. Arrowheads depict soma of GFP-labeled, lumbar 
motor neurons. Scale bars - 200 µm. 
  
 
 
Fig. S. High content analysis (HCA) of neuronal morphology following miR-218 
perturbation. Primary motor neurons were plated in a 384-well plate, transduced with control, 
miR-218 OE or miR-218 inhibitor encoding lentiviruses and stained at 4 DIV. Neuron-specific 
class III beta-tubulin (Tuj1) was used to visualize neuronal processed and DAPI for visualization 
of nuclei. Phenotypic parameters were quantified using MetaXpress High-Content Image 
Acquisition and Analysis Software (Molecular Devices) set to identify and measure only cellular 
processes connected to cell bodies. (A) Cell number. Only nuclei of cells expressing Tuj1 were 
counted. (B) Mean number of branches per cell. (C) Mean axonal outgrowth per cell. Data 
normalized to control virus transduced cells. n=24 independent wells per experimental condition, 
in two technical duplicates, each. This experiment was repeated 3 independent times with similar 
results. Error bars, mean ± SEM. One-ZD\ $129$ IROORZHG E\ %RQIHUURQLH¶V PXOWLSOH
comparison test. ns ± non-significant. 
 
  
  
 
 
Fig. S3. miR-218 regulates intrinsic excitability. (A) Representative traces depicting repetitive 
firing, following miR-218 perturbation. Recordings of rat hippocampal neurons, transduced with 
lentiviruses encoding mCherry alone (control), miR-218 overexpression (miR-218 OE) or a miR-
218 knockdown (miR-218 KD) inhibitor, following injection of 300pA depolarizing current for 
500ms. Injected current amplitude and duration are illustrated in the lower pane. (B) Quantification 
of firing rates. (C) Representative traces depicting rheobase - current input required to generate 
action potential. (D) Quantification of rheobase; (E) spike threshold; (F) resting membrane 
potential (RMP). Control, n=44; miR-218 OE, n=65; miR-218 KD, n=30. Data was combined from 
4 independent experiments. Kruskal-:DOOLVWHVWDQG'XQQ¶VPXltiple comparison test. Error bars, 
mean ±SEM, * P<0.05; ** P<0.01; *** P<0.001; ns - non-significant. 
  
 
 
Fig. S4. qPCR validation of miR-218 target knockdown. Targeting and non-targeting control 
siRNAs (Integrated DNA Technologies, Inc.) were HQFDSVXODWHG LQ 1HXUR QDQRSDUWLFOHV
(Precision NanoSystems, Inc.). Primary motor neurons were transfected with siRNA at a final 
conFHQWUDWLRQRIȝJPODW DIV. At 12 DIV RNA was extracted and expression of miR-218 
targets was analyzed by qPCR. Data normalized to average expression of HPRT and ȕ±actin. n=3 
independent wells per experimental condition, in two technical duplicates, each. Error bars, mean 
± SEM. Two-sided student t-test. ** P<0.01; *** P<0.001. 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
Fig. S5. Evaluation of miR-218 upstream of the mRNA encoding for the potassium channel 
Kv4.2 (Kcnd2). (A) Relative Renilla luminescence upstream of a wild-W\SH.Yƍ875RUD
PXWDWHGƍ875WKDWLVLQVHQVLWLYHWRPL5-218, normalized to co-expressed firefly luciferase and to 
a negative control miRNA vector. n=3 independent wells per experimental condition. One-way 
ANOVA folloZHG E\ %RQIHUURQLH¶V PXOWLSOH FRPSDULVRQ WHVW (UURU EDUV PHDQ  6(0 *** 
P<0.001. (B) AGO2 CLEAR-CLIP experiment did not identify a miR-.Y¶875FKLPHUD
in mouse cortex (29), as opposed to the miR-.Y¶875FKLPHUDin main Fig. 3J. (C,D) 
Western blot studies of Kv4.2 protein expression, in primary rat motor neurons, presented as 
boxplot (median, upper / lower quartiles & extreme points), upon (C) miR-218 knockdown (miR-
218 KD, n=3) or overexpression (miR-218 OE, n=3), relative to Control (n=3). One-way ANOVA 
followed by Newman-Keuls multiple comparison test, and a validation study of (D) miR-218 KD 
  
(n=3), relative to Control (n=3). Two-sided student t-test. (E) Kv4.2 mRNA expression, as log2 
normalized counts, from NGS study of induced ALS motor neurons (n=4 different donors in 
duplicates) or non-neurodegeneration controls (n=3 different donors in duplicates; (30)). Box-Plots 
depict median, upper / lower quartiles & extreme points, DESeq analysis. Non-significant 
difference. (F) Kv4.2 mRNA expression, as Reads Per Kilobase Million (RPKM) from NGS study 
of laser capture microdissection-enriched surviving motor neurons from lumbar spinal cords of 
patients with sALS with rostral onset and caudal progression (n=12) and non-neurodegeneration 
controls (n=9; (21), GSE76220). Box-Plots depict median, upper / lower quartiles & extreme 
points, two-VLGHGVWXGHQW¶VW-test. Non-significant difference. 
 
 
 
  
  
 
 
Fig. S6. Kv10.1 (Kcnh1) protein quantification by western blot, following miR-218 KD. A 
western blot validation study of Kv10.1 protein expression upon miR-218 KD (n=3), in primary rat 
motor neurons, relative to Control (n=3). Box-Plots depict median, upper / lower quartiles & 
extreme points, two-sided student t-test. *** P<0.001.  
  
 
Fig. S7. A summary diagram of key observations. (left) Human pathology: miR-218 expression 
is reduced in ALS ventral horns, because of both molecular downregulation and of motor neuron 
loss. Accordingly, mRNA targets of miR-218 are reciprocally upregulated (de-repressed). miR-218 
might serve as a biomarker of motor neuron mass. (center) miR-218 regulates neuronal activity 
upstream of the voltage gated potassium channel Kv10.1 (Kcnh1). (right) Human genetics: rare 
genetic variants identified in patients with ALS, in the sequence of the pre-miR-218-2 gene, 
dysregulate miR-218 biogenesis and impair regulation of neuron activity. miR-218 contributes to 
motor neuron specificity and its function may be particularly susceptible to failure in motor neuron 
diseases. Therefore, the work connects human genetics and human neuropathology to motor 
neuron-specific functions via a small non coding RNA. 
  
  
Table S1. Identified hsa-miR-218-2 variants. 
 
Ref, Reference allele; Alt, Alternate allele. 
  
TOPMed
cases
(n= 4281)
controls
(n=1838)
cases
(n=3457)
controls 
(n=7034)
controls
(n=62784)
cases
(n=7738)
controls
(n=71656)
V1 Chr5:168,195,208 (-) C A rs751147155 2.3 x 10
-4 0 1.3 x 10
-4 0
V2 Chr5:168,195,207 (-) G A rs374716278 2.3 x 10
-4 0 2.9 x 10
-4 0 0.5 x 10
-4
2.6 x 10
-4
0.4 x 10
-4
V3 Chr5:168,195,199 (-) C T rs773402384 0 5.4 x 10
-4 0 0.1 x 10
-4
V4 Chr5:168,195,176 (-) C T rs368624931 2.3 x 10
-4 0 2.9 x 10
-4 0 2.6 x 10
-4 0
V5 Chr5:168,195,174 (-) C T rs140638702 9.3 x 10
-4
5.4 x 10
-4
11.6 x 10
-4
4.3 x 10
-4
3.2 x 10
-4
10.3 x 10
-4
3.3 x 10
-4
V6 Chr5:168,195,173 (-) G A rs780192152 4.7 x 10
-4 0 0 1.4 x 10
-4
1.1 x 10
-4
2.6 x 10
-4
1.1 x 10
-4
V7 Chr5:168,195,198 (-) G A rs770316009 0.5 x 10
-4 0 0.4 x 10
-4
V8 Chr5:168,195,196 (-) A G rs372358902 0.5 x 10
-4 0 0.4 x 10
-4
V9 Chr5:168,195,175 (-) G A rs758061075 0.2 x 10
-4 0 0.1 x 10
-4
Total 21.0 x 10
-4
10.9 x 10
-4
17.4 x 10
-4
5.7 x 10
-4
5.9 x 10
-4
19.4 x 10
-4
6.0 x 10
-4
Minor Allele Frequency
Discovery Replication Total
Variant
Position
(GRCh37/hg19)
Ref Alt dbSNP ID
  
Table S2. DsiRNA sequences employed in the study. 
Oligo 
name 
S-strand AS-strand 
has-miR-
214-3p 
mimic 
5'-phos-
rArCrArGrCrArGrGrCrArCrArGrAr
CrArGrGrCmAmGmU-3' 
5'-
mUmGrCmCrUmGrUmCrUmGrUmGr
CmCrUmGrCmUrGrU-3' 
NC5 
siRNA 
5'-
rCrGrCrGrArCrUrArUrArCrGrCrGr
CrArArUrArUmGmGrU-3' 
5'-
rUmCrCmArUmArAmArGmUrAmGrG
mArAmArCmArCmUrAmCA-3' 
Rat 
Cacnb4 
siRNA 
5'-
mGmUrCmUrAmCrCrUrGrArGmCr
AmUrGmUrUmGrArArArUrCmAA-
3' 
5'-
rUrUmGrArUrUrUrCmArAmCrAmUr
GrCrUrCrArGrGrUrAmGrAmCmUmU
-3' 
Rat Kcnd2 
siRNA 
5'-
mUmGrCmArAmGrArArCrUrCmAr
GmUrAmCrAmArUrUrCrArGmAT-
3' 
5'-
rArUmCrUrGrArArUmUrGmUrAmCr
UrGrArGrUrUrCrUrUmGrCmAmCmG
-3' 
Rat Kcnh1 
siRNA 
5'-
mGmCrUmGrAmGrArGrGrArUmCr
AmUrUmUrCmArArArArCrAmAA-
3' 
5'-
rUrUmUrGrUrUrUrUmGrAmArAmUr
GrArUrCrCrUrCrUrCmArGmCmUmU-
3' 
Rat Slc6a1 
siRNA 
5'-
rCrCrArArArUrGrArCrArGrArUrGr
GrGrCrUrArGrArCrAAG-3' 
5'-
rCrUrUrGrUrCrUrArGrCrCrCrArUrCr
UrGrUrCrArUrUrUrGrGrUrG-3' 
5'-
rCrCrCrArUrGrUrArGrCrArArArGr
CrGrUrArUrArUrGrUCT-3' 
5'-
rArGrArCrArUrArUrArCrGrCrUrUrUr
GrCrUrArCrArUrGrGrGrArG-3' 
5'-
rArCrCrUrUrArUrArGrArGrCrArCr
ArArCrGrUrUrArArGGG-3' 
5'-
rCrCrCrUrUrArArCrGrUrUrGrUrGrCr
UrCrUrArUrArArGrGrUrUrA-3' 
5'-
rGrGrArGrArArGrArCrUrCrArUrAr
GrCrArGrArGrArArCTA-3' 
5'-
rUrArGrUrUrCrUrCrUrGrCrUrArUrGr
ArGrUrCrUrUrCrUrCrCrUrA-3' 
5'-
rCrArArArUrGrArUrArUrCrArCrAr
ArCrUrArGrArGrCrACG-3' 
5'-
rCrGrUrGrCrUrCrUrArGrUrUrGrUrGr
ArUrArUrCrArUrUrUrGrArU-3' 
5'-
rCrCrUrUrArArUrArArCrUrArUrGr
GrUrGrArArUrArArCTG-3' 
5'-
rCrArGrUrUrArUrUrCrArCrCrArUrAr
GrUrUrArUrUrArArGrGrArU-3' 
5'-
rGrCrArArArCrArGrCrCrUrArUrCr
CrArGrArArGrArGrCTC-3' 
5'-
rGrArGrCrUrCrUrUrCrUrGrGrArUrAr
GrGrCrUrGrUrUrUrGrCrUrG-3' 
5'-
rArGrCrArUrCrArArGrCrArCrArCr
UrGrUrArGrArGrArATG-3' 
5'-
rCrArUrUrCrUrCrUrArCrArGrUrGrUr
GrCrUrUrGrArUrGrCrUrCrU-3' 
5'-
rCrCrArGrArGrGrGrArArGrArArGr
ArUrArArUrUrGrUrATT-3' 
5'-
rArArUrArCrArArUrUrArUrCrUrUrCr
UrUrCrCrCrUrCrUrGrGrGrC-3' 
  
5'-
rGrCrArCrArCrCrArGrUrUrCrUrUr
GrCrArArUrArArGrCTA-3' 
5'-
rUrArGrCrUrUrArUrUrGrCrArArGrAr
ArCrUrGrGrUrGrUrGrCrUrG-3' 
5'-
rGrCrArGrUrArUrArUrUrUrCrArUr
GrUrUrUrGrArArArGCA-3' 
5'-
rUrGrCrUrUrUrCrArArArCrArUrGrAr
ArArUrArUrArCrUrGrCrArU-3' 
5'-
rGrArArCrArUrUrUrArUrUrArCrAr
UrUrGrUrCrArUrCrATC-3' 
5'-
rGrArUrGrArUrGrArCrArArUrGrUrAr
ArUrArArArUrGrUrUrCrArG-3' 
5'-
rGrArUrUrUrArUrUrCrUrCrArGrAr
ArCrArCrCrArArGrUAA-3' 
5'-
rUrUrArCrUrUrGrGrUrGrUrUrCrUrGr
ArGrArArUrArArArUrCrCrU-3' 
5'-
rArGrArArGrArUrArArUrUrGrUrAr
UrUrArUrCrArUrArUAT-3' 
5'-
rArUrArUrArUrGrArUrArArUrArCrAr
ArUrUrArUrCrUrUrCrUrUrC-3' 
5'-
rCrArGrUrUrCrUrUrGrCrArArUrAr
ArGrCrUrArUrCrUrCCC-3' 
5'-
rGrGrGrArGrArUrArGrCrUrUrArUrUr
GrCrArArGrArArCrUrGrGrU-3' 
5'-
rCrArCrCrArArGrUrArArArUrUrUr
ArUrCrUrCrUrArUrATA-3' 
5'-
rUrArUrArUrArGrArGrArUrArArArUr
UrUrArCrUrUrGrGrUrGrUrU-3' 
5'-
rGrArUrUrGrCrUrCrUrGrGrGrArAr
GrCrUrArCrArArCrUCT-3' 
5'-
rArGrArGrUrUrGrUrArGrCrUrUrCrCr
CrArGrArGrCrArArUrCrArG-3' 
5'-
rCrArArGrUrCrUrUrUrUrUrUrGrAr
GrArUrArArArUrGrCAG-3' 
5'-
rCrUrGrCrArUrUrUrArUrCrUrCrArAr
ArArArArGrArCrUrUrGrUrU-3' 
5'-
rCrArArArUrGrArUrArUrCrArCrAr
ArCrUrArGrArGrCrACG-3' 
5'-
rCrGrUrGrCrUrCrUrArGrUrUrGrUrGr
ArUrArUrCrArUrUrUrGrArU-3' 
5'-
rUrCrGrArUrGrUrUrCrUrUrUrGrAr
UrGrGrArArArArCrUGA-3' 
5'-
rUrCrArGrUrUrUrUrCrCrArUrCrArAr
ArGrArArCrArUrCrGrArGrC-3' 
Rat 
Gabrb2 
siRNA 
5'-
rArCrCrUrArCrUrUrCrCrUrGrArAr
UrGrArUrArArGrArAGT-3' 
5'-
rArCrUrUrCrUrUrArUrCrArUrUrCrAr
GrGrArArGrUrArGrGrUrGrU-3' 
5'-
rGrArArUrArUrGrCrUrUrUrGrGrUr
CrArArCrUrArCrArUCT-3' 
5'-
rArGrArUrGrUrArGrUrUrGrArCrCrAr
ArArGrCrArUrArUrUrCrCrA-3' 
5'-
rGrCrArCrUrCrUrUrGrArGrArUrAr
ArArArArArUrGrArGAT-3' 
5'-
rArUrCrUrCrArUrUrUrUrUrUrArUrCr
UrCrArArGrArGrUrGrCrUrG-3' 
5'-
rCrUrGrArArGrUrCrArArUrArUrGr
GrArCrUrArCrArCrCTT-3' 
5'-
rArArGrGrUrGrUrArGrUrCrCrArUrAr
UrUrGrArCrUrUrCrArGrArA-3' 
5'-
rGrUrGrGrCrArGrUrArGrGrArArUr
GrArArCrArUrUrGrATA-3' 
5'-
rUrArUrCrArArUrGrUrUrCrArUrUrCr
CrUrArCrUrGrCrCrArCrArG-3' 
  
5'-
rCrArArCrUrGrArUrGrArCrArUrUr
GrArGrUrUrUrUrArCTG-3' 
5'-
rCrArGrUrArArArArCrUrCrArArUrGr
UrCrArUrCrArGrUrUrGrUrA-3' 
5'-
rCrArUrCrArGrArArGrCrArGrUrAr
ArUrGrGrGrArCrUrUGG-3' 
5'-
rCrCrArArGrUrCrCrCrArUrUrArCrUr
GrCrUrUrCrUrGrArUrGrUrG-3' 
5'-
rUrArCrUrCrArGrCrArCrUrCrUrUr
GrArGrArUrArArArAAA-3' 
5'-
rUrUrUrUrUrUrArUrCrUrCrArArGrAr
GrUrGrCrUrGrArGrUrArArG-3' 
5'-
rGrUrCrCrUrGrArCrGrArUrGrArCr
CrArCrArArUrCrArATA-3' 
5'-
rUrArUrUrGrArUrUrGrUrGrGrUrCrAr
UrCrGrUrCrArGrGrArCrArG-3' 
5'-
rGrArUrArArGrArArGrUrCrArUrUr
UrGrUrArCrArUrGrGAG-3' 
5'-
rCrUrCrCrArUrGrUrArCrArArArUrGr
ArCrUrUrCrUrUrArUrCrArU-3' 
5'-
rArGrArCrUrGrUrCrCrUrArCrArAr
UrGrUrArArUrCrCrCTT-3' 
5'-
rArArGrGrGrArUrUrArCrArUrUrGrUr
ArGrGrArCrArGrUrCrUrCrU-3' 
5'-
rArCrUrUrCrArUrCrCrUrGrCrArGr
ArCrArUrArCrArUrGCC-3' 
5'-
rGrGrCrArUrGrUrArUrGrUrCrUrGrCr
ArGrGrArUrGrArArGrUrArG-3' 
5'-
rUrCrArArUrGrArCrCrCrUrArGrUr
ArArUrArUrGrUrCrGCT-3' 
5'-
rArGrCrGrArCrArUrArUrUrArCrUrAr
GrGrGrUrCrArUrUrGrArCrA-3' 
5'-
rGrGrArArUrArUrGrCrUrUrUrGrGr
UrCrArArCrUrArCrATC-3' 
5'-
rGrArUrGrUrArGrUrUrGrArCrCrArAr
ArGrCrArUrArUrUrCrCrArG-3' 
5'-
rGrGrArArUrGrArArCrArUrUrGrAr
UrArUrCrGrCrCrArGCA-3' 
5'-
rUrGrCrUrGrGrCrGrArUrArUrCrArAr
UrGrUrUrCrArUrUrCrCrUrA-3' 
5'-
rCrCrArCrArUrCrArGrArArGrCrAr
GrUrArArUrGrGrGrACT-3' 
5'-
rArGrUrCrCrCrArUrUrArCrUrGrCrUr
UrCrUrGrArUrGrUrGrGrCrC-3' 
5'-
rArGrArArArGrCrUrGrCrUrArArUr
GrCrCrArArCrArArCGA-3' 
5'-
rUrCrGrUrUrGrUrUrGrGrCrArUrUrAr
GrCrArGrCrUrUrUrCrUrCrA-3' 
5'-
rGrGrArCrUrArCrArCrCrUrUrGrAr
CrCrArUrGrUrArUrUTC-3' 
5'-
rGrArArArUrArCrArUrGrGrUrCrArAr
GrGrUrGrUrArGrUrCrCrArU-3' 
5'-
rArGrArArUrCrArCrArArCrUrArCr
ArGrCrUrGrCrCrUrGCA-3' 
5'-
rUrGrCrArGrGrCrArGrCrUrGrUrArGr
UrUrGrUrGrArUrUrCrUrGrA-3' 
5'-
rArGrArUrUrGrUrCrCrCrUrArArGr
CrUrUrUrArArGrCrUGA-3' 
5'-
rUrCrArGrCrUrUrArArArGrCrUrUrAr
GrGrGrArCrArArUrCrUrGrG-3' 
Rat 
Gabrg1 
siRNA 
5'-
rGrUrCrUrArCrCrArGrUrUrArArAr
ArUrCrUrGrArArUrCAT-3' 
5'-
rArUrGrArUrUrCrArGrArUrUrUrUrAr
ArCrUrGrGrUrArGrArCrUrU-3' 
  
5'-
rArArArUrCrUrGrArArUrCrArUrUr
UrGrGrUrCrArUrArUGA-3' 
5'-
rUrCrArUrArUrGrArCrCrArArArUrGr
ArUrUrCrArGrArUrUrUrUrA-3' 
5'-
rCrUrGrGrCrUrUrArGrUrCrCrArAr
UrArUrArArUrCrArCTT-3' 
5'-
rArArGrUrGrArUrUrArUrArUrUrGrGr
ArCrUrArArGrCrCrArGrArU-3' 
5'-
rCrUrArCrCrArGrUrUrArArArArUr
CrUrGrArArUrCrArUTT-3' 
5'-
rArArArUrGrArUrUrCrArGrArUrUrUr
UrArArCrUrGrGrUrArGrArC-3' 
5'-
rArCrUrGrGrArArUrUrUrUrCrArAr
GrCrUrArUrGrGrArUAC-3' 
5'-
rGrUrArUrCrCrArUrArGrCrUrUrGrAr
ArArArUrUrCrCrArGrUrGrG-3' 
5'-
rCrArGrUrArArUrUrGrArArArCrUr
GrArUrGrUrUrUrArUGT-3' 
5'-
rArCrArUrArArArCrArUrCrArGrUrUr
UrCrArArUrUrArCrUrGrUrG-3' 
5'-
rGrUrGrArGrGrUrUrGrArUrArUrUr
CrUrUrGrUrUrArCrUAA-3' 
5'-
rUrUrArGrUrArArCrArArGrArArUrAr
UrCrArArCrCrUrCrArCrUrC-3' 
5'-
rCrCrUrArArGrGrUrUrUrCrUrUrAr
CrGrUrGrArCrArGrCAA-3' 
5'-
rUrUrGrCrUrGrUrCrArCrGrUrArArGr
ArArArCrCrUrUrArGrGrUrA-3' 
5'-
rCrUrUrGrCrArUrUrArUrUrUrUrAr
CrUrArGrUrArArCrAAT-3' 
5'-
rArUrUrGrUrUrArCrUrArGrUrArArAr
ArUrArArUrGrCrArArGrGrU-3' 
5'-
rGrArArUrUrArUrUrCrArGrGrUrUr
ArArUrUrUrArCrCrUAA-3' 
5'-
rUrUrArGrGrUrArArArUrUrArArCrCr
UrGrArArUrArArUrUrCrUrU-3' 
5'-
rGrGrCrUrArUrGrArUrArArCrArAr
ArCrUrUrCrGrUrCrCAG-3' 
5'-
rCrUrGrGrArCrGrArArGrUrUrUrGrUr
UrArUrCrArUrArGrCrCrUrU-3' 
5'-
rUrGrArCrArArCrCrCrUrCrArGrUr
ArCrArArUrCrGrCrUAG-3' 
5'-
rCrUrArGrCrGrArUrUrGrUrArCrUrGr
ArGrGrGrUrUrGrUrCrArUrA-3' 
5'-
rCrCrUrUrUrGrUrArGrGrGrUrUrAr
ArGrArArArUrUrCrAAC-3' 
5'-
rGrUrUrGrArArUrUrUrCrUrUrArArCr
CrCrUrArCrArArArGrGrCrA-3' 
5'-
rGrGrArGrUrCrArArArCrUrArGrAr
GrGrArGrUrGrArGrGTT-3' 
5'-
rArArCrCrUrCrArCrUrCrCrUrCrUrAr
GrUrUrUrGrArCrUrCrCrArC-3' 
5'-
rGrGrArArCrUrCrArArGrGrArArAr
UrCrUrGrArUrGrCrGCA-3' 
5'-
rUrGrCrGrCrArUrCrArGrArUrUrUrCr
CrUrUrGrArGrUrUrCrCrUrG-3' 
5'-
rCrCrCrArCrArGrUrArArUrUrGrAr
ArArCrUrGrArUrGrUTT-3' 
5'-
rArArArCrArUrCrArGrUrUrUrCrArAr
UrUrArCrUrGrUrGrGrGrUrC-3' 
5'-
rCrCrArUrGrArArCrArArCrArUrUr
UrCrUrArUrGrCrCrUCA-3' 
5'-
rUrGrArGrGrCrArUrArGrArArArUrGr
UrUrGrUrUrCrArUrGrGrGrA-3' 
  
5'-
rCrCrArArUrArUrArArUrCrArCrUr
UrCrGrArUrUrUrCrATA-3' 
5'-
rUrArUrGrArArArUrCrGrArArGrUrGr
ArUrUrArUrArUrUrGrGrArC-3' 
5'-
rGrGrArUrGrGrGrCrUrArUrUrUrCr
ArCrArArUrUrCrArGAC-3' 
5'-
rGrUrCrUrGrArArUrUrGrUrGrArArAr
UrArGrCrCrCrArUrCrCrGrU-3' 
5'-
rArArCrArUrGrGrArGrUrArCrArCr
GrArUrArGrArCrArUCA-3' 
5'-
rUrGrArUrGrUrCrUrArUrCrGrUrGrUr
ArCrUrCrCrArUrGrUrUrUrA-3' 
U$U&U*U8 51$P$P&P*P8 ¶20H51$$*&7 '1$SKRV SKRVSKDWH 
  
  
Table S3. Synthetic miR-218 sequences used for cloning into pMA-T vectors. 
Variant Synthetic gene sequence 
WT miR-
218 
5'-
CTGTGTCTCCCGCGGATCCGCGCTGGGGTGGGGCACAAGGGCAGCAGGGC
TGCAATCTTCGGAAGTGTTCCAGTGGAACCCCACTCCTGATACTAATCACG
CTCAGTGGGGGCCTGCTCCGGCTTCCGCTTCTCCACGCTGCTTCCTCTGAG
CGCTCCTGTCCTCTCTCTGACGCTGCTTCCTGACCTTGACTCTGACCAGTC
GCTGCGGGGCTTTCCTTTGTGCTTGATCTAACCATGTGGTGGAACGATGGA
AACGGAACATGGTTCTGTCAAGCACCGCGGAAAGCACCGTGCTCTCCTGC
AGCATGGCCCGCCACCGCCGCCACCACCGCTGGACACCTCTCCTCTGCTCT
GGAGCACCGCAGCCCACCACCTGCCAGACCCACCTCTCCCAGTCTCAACT
CACCAAAGGCAGGAGGGTAGGAGTCTCAAAGGATGCAGATACAGAGGGA
AATGGGTCTGGAGAAGCACCCTGGCCGGAATTCCGGGGAAAGAGAT-3' 
V2 
5'-
CTGTGTCTCCCGCGGATCCGCGCTGGGGTGGGGCACAAGGGCAGCAGGGC
TGCAATCTTCGGAAGTGTTCCAGTGGAACCCCACTCCTGATACTAATCACG
CTCAGTGGGGGCCTGCTCCGGCTTCCGCTTCTCCACGCTGCTTCCTCTGAG
CGCTCCTGTCCTCTCTCTGACGCTGCTTCCTGACCTTGACTCTGACCAGTC
GCTGCGGGGCTTTCCTTTGTGCTTGATCTAACCATGTGGTGGAACAATGGA
AACGGAACATGGTTCTGTCAAGCACCGCGGAAAGCACCGTGCTCTCCTGC
AGCATGGCCCGCCACCGCCGCCACCACCGCTGGACACCTCTCCTCTGCTCT
GGAGCACCGCAGCCCACCACCTGCCAGACCCACCTCTCCCAGTCTCAACT
CACCAAAGGCAGGAGGGTAGGAGTCTCAAAGGATGCAGATACAGAGGGA
AATGGGTCTGGAGAAGCACCCTGGCCGGAATTCCGGGGAAAGAGAT-3' 
V5 
5'-
CTGTGTCTCCCGCGGATCCGCGCTGGGGTGGGGCACAAGGGCAGCAGGGC
TGCAATCTTCGGAAGTGTTCCAGTGGAACCCCACTCCTGATACTAATCACG
CTCAGTGGGGGCCTGCTCCGGCTTCCGCTTCTCCACGCTGCTTCCTCTGAG
CGCTCCTGTCCTCTCTCTGACGCTGCTTCCTGACCTTGACTCTGACCAGTC
GCTGCGGGGCTTTCCTTTGTGCTTGATCTAACCATGTGGTGGAACGATGGA
AACGGAACATGGTTCTGTCAAGCACCGTGGAAAGCACCGTGCTCTCCTGC
AGCATGGCCCGCCACCGCCGCCACCACCGCTGGACACCTCTCCTCTGCTCT
GGAGCACCGCAGCCCACCACCTGCCAGACCCACCTCTCCCAGTCTCAACT
CACCAAAGGCAGGAGGGTAGGAGTCTCAAAGGATGCAGATACAGAGGGA
AATGGGTCTGGAGAAGCACCCTGGCCGGAATTCCGGGGAAAGAGAT-3' 
Vall 
5'-
CTGTGTCTCCCGCGGATCCGCGCTGGGGTGGGGCACAAGGGCAGCAGGGC
TGCAATCTTCGGAAGTGTTCCAGTGGAACCCCACTCCTGATACTAATCACG
CTCAGTGGGGGCCTGCTCCGGCTTCCGCTTCTCCACGCTGCTTCCTCTGAG
CGCTCCTGTCCTCTCTCTGACGCTGCTTCCTGACCTTGACTCTGACTAGTCG
CTGCGGGGCTTTCCTTTGTGCTTGATCTAACCATGTGGTGGAAAAATGGAA
ACGGAACATGGTTCTGTCAAGCACTGTAGAAAGCACCGTGCTCTCCTGCA
GCATGGCCCGCCACCGCCGCCACCACCGCTGGACACCTCTCCTCTGCTCTG
GAGCACCGCAGCCCACCACCTGCCAGACCCACCTCTCCCAGTCTCAACTC
ACCAAAGGCAGGAGGGTAGGAGTCTCAAAGGATGCAGATACAGAGGGAA
ATGGGTCTGGAGAAGCACCCTGGCCGGAATTCCGGGGAAAGAGAT-3' 
  
Vdead 
5'-
CTGTGTCTCCCGCGGATCCGCGCTGGGGTGGGGCACAAGGGCAGCAGGGC
TGCAATCTTCGGAAGTGTTCCAGTGGAACCCCACTCCTGATACTAATCACG
CTCAGTGGGGGCCTGCTCCGGCTTCCGCTTCTCCACGCTGCTTCCTCTGAG
CGCTCCTGTCCTCTCTCTGACGCTGCTTCCTGACCTTGACTCTGACCAGTC
GCTGCGGGAACCCAATTTGTGCTTGATCTAACCATGTGGTGGAACGATGG
AAACGGAACATGGTTCTGTCAAGCACCGCGGAAAGCACCGTGCTCTCCTG
CAGCATGGCCCGCCACCGCCGCCACCACCGCTGGACACCTCTCCTCTGCTC
TGGAGCACCGCAGCCCACCACCTGCCAGACCCACCTCTCCCAGTCTCAAC
TCACCAAAGGCAGGAGGGTAGGAGTCTCAAAGGATGCAGATACAGAGGG
AAATGGGTCTGGAGAAGCACCCTGGCCGGAATTCCGGGGAAAGAGAT-3' 
pre-miR-218 sequence (Blue); variants (Red) 
 
 
 
 
 
 
 
  
  
Table S4. Primers used for quantitative real-time PCR. 
Gene Forward (5' to 3') Reverse (5' to 3') 
miR-218-5p TTGTGCTTGATCTAACCATGT NA 
RNU6B (U6) GATGACACGCAAATTCGTGAA NA 
hHPRT ACTTTGCTTTCCTTGGTCAGGCAGT CGTGGGGTCCTTTTCACCAGCA 
hGAPDH TTCTTTTGCGTCGCCAGCCGA GTGACCAGGCGCCCAATACGA 
hHB9 GGAGCACCAGTTCAAGCTCA AATCTTCACCTGGGTCTCGGT 
hISL1 CAGTCCAGAGAGACACGACG AATTGACCAGTTGCTGAAAAGC 
hChAT AAGGAAGGTCCACACCTCTG TCAGACACCAAGTGTCGCAT 
Rat Hprt CGAGATGCTATGAAGGAGATGG GTAATCCAGCAGGTCAGCAAAG 
Rat Gapdh CCTTTAGTGGGCCCTCGG GCCTGGAGAAACCTGCCAAG 
Rat Kcnd2 CAAGTTCACCAGCATCCCT CCCGAAAATCTTCCCTGCTAT 
Rat Kcnh1 ACCTGATTCTCACCTACAATCTG TCTTCCGTTTCATCCTCTCCT 
Rat Cacnb4 CACCGTATCCCACAGCAAT GAGGTCATTAGGCTTCGTCTT 
Rat Slc6a1 CCCAGGGTGGCATTTATGTCT GGGTGTGAAAAAGGACCAGC 
Rat Gabrb2 AAGATGCGCCTGGATGTCAA ATGCTGGAGGCATCATAGGC 
Rat Gabrg1 GTCTTCCTTTTCTCTCCTTCCC TCATCTTCATCATCTGCTTTATCAATG 
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